Markus G. Manz

Zurich, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 253 publications

CD117-targeted HCT preconditioning in AML and MDS.

CD117-targeted HCT preconditioning in AML and MDS.

Journal: Blood

Published: May 28, 2026

Autologous stem cell transplantation versus consolidation chemotherapy as postremission treatment in newly diagnosed favorable- and intermediate-risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials.

Autologous stem cell transplantation versus consolidation chemotherapy as postremission treatment in newly diagnosed favorable- and intermediate-risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials.

Journal: HemaSphere

Published: April 21, 2026

IL-1-mediated cancer-adapted hematopoiesis in aging and clonal hematopoiesis.

IL-1-mediated cancer-adapted hematopoiesis in aging and clonal hematopoiesis.

Journal: Seminars in immunology

Published: April 08, 2026

A fluorescein-conjugated somatostatin receptor antagonist adapter for chimeric antigen receptor T cell therapy of meningioma.

A fluorescein-conjugated somatostatin receptor antagonist adapter for chimeric antigen receptor T cell therapy of meningioma.

Journal: Neuro-oncology advances

Published: March 17, 2026

Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.

Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.

Journal: HemaSphere

Published: February 26, 2026

Extracorporeal photopheresis alone or in combination with ruxolitinib for the treatment of chronic graft-versus-host disease.

Extracorporeal photopheresis alone or in combination with ruxolitinib for the treatment of chronic graft-versus-host disease.

Journal: Frontiers in immunology

Published: February 03, 2026

Genetic resistance to leukemia.

Genetic resistance to leukemia.

Journal: Science (New York, N.Y.)

Published: January 01, 2026

Quantifying target antigen-dependent CAR T-cell performance against AML.

Quantifying target antigen-dependent CAR T-cell performance against AML.

Journal: Cancer cell international

Published: November 18, 2025

Enhancement of CD117-Targeted Bispecific T-cell Engagement by CD33-Targeted Bispecific T-cell Costimulation in Acute Myeloid Leukemia.

Enhancement of CD117-Targeted Bispecific T-cell Engagement by CD33-Targeted Bispecific T-cell Costimulation in Acute Myeloid Leukemia.

Journal: Cancer research communications

Published: November 02, 2025

Class 3 MAP2K1 mutations associate with relapse and multiple treatment lines in multisystem Langerhans cell histiocytosis.

Class 3 MAP2K1 mutations associate with relapse and multiple treatment lines in multisystem Langerhans cell histiocytosis.

Journal: Blood advances

Published: October 22, 2025

Class 3 MAP2K1 mutations are associated with frequent relapse and multiple treatment lines in multi-system Langerhans cell histiocytosis.

Class 3 MAP2K1 mutations are associated with frequent relapse and multiple treatment lines in multi-system Langerhans cell histiocytosis.

Journal: Blood advances

Published: October 22, 2025

Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy versus liposomal cytarabine and daunorubicin.

Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy versus liposomal cytarabine and daunorubicin.

Journal: Haematologica

Published: October 16, 2025

Showing 1-12 of 253

Last Updated: 09/26/2026